share_log

Argus Research Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

Argus Research Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $920

阿格斯研究维持对Regeneron Pharmicals的买入,将目标股价上调至920美元
Benzinga ·  2023/09/15 11:03

Argus Research analyst Jasper Hellweg maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $825 to $920.

阿格斯研究分析师贾斯珀·赫尔维格维持Regeneron Pharmicals(纳斯达克股票代码:REGN)的买入,并将目标股价从825美元上调至920美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发